Cell X Technologies has announced a collaboration with BioLamina to integrate BioLamina’s defined laminin reagents (Biolaminin®) with the Cell X Celligent™ platform. The goal is to reduce variability and improve reproducibility in advanced therapy manufacturing.

The partnership focuses on combining automation with standardized, high-quality reagents to support scalable and GMP-compliant (Good Manufacturing Practice) workflows for next-generation therapies. By using BioLamina’s full-length, human recombinant laminin-521 and laminin-511 isoforms—including both research-use-only and GMP-compatible versions—within automated workflows, the two companies aim to streamline iPSC (induced pluripotent stem cell) culture and differentiation, while reducing operator-dependent variability.

Lynne Frick, CEO of Cell X Technologies, stated: “Cell X Technologies is committed to advancing automation in regenerative medicine by ensuring that best-in-class reagents are seamlessly integrated into our automated workflows for process characterization, development and manufacturing. Our collaboration with BioLamina reflects a shared vision of reducing variability and increasing successes, especially during the critical transition from research to clinical application.”

Klaus Langhoff-Roos, CEO of BioLamina, commented: “Standardization, reproducibility, and physiological relevance are at the core of BioLamina’s mission to improve patient outcomes and save lives. Partnering with Cell X Technologies enables us to showcase how full-length equals full-function. This, when combined with advanced automation platforms, can drive predictable consistency and scalability for iPSC-based manufacturing.”

According to the companies, this combination is intended to support robust, reproducible, and regulator-ready cell therapy processes, facilitating reliable therapeutic development and manufacturing in regenerative medicine.

Want to keep up on regenerative medicine? Get the weekly newsletter here.